{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:42:34Z","timestamp":1761129754334,"version":"3.40.5"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN\u2010UK\u2010311\u20104340"],"award-info":[{"award-number":["IN\u2010UK\u2010311\u20104340"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to analyse and compare estimated glomerular filtration rate (eGFR) slopes during exposure to tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) in individuals who initiated TAF, regardless of prior regimen, before October 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational cohort study was conducted at 11 clinics in the UK and Ireland. Mixed effects models with random intercept and time terms fitted were used to generate and compare eGFR slopes while participants were exposed to TDF and TAF, with adjustment for age, eGFR at TDF\/TAF initiation, gender, ethnicity, and time\u2010updated CD4 cell count and HIV RNA measurements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data were available for 357 subjects (median age 50\u00a0years; 80% male; 82% white\/other ethnicity; 51% men who have sex with men; median nadir CD4 count 216\u00a0cells\/\u00b5L). The median duration of exposure to TAF was 2.0 (interquartile range 1.6, 2.3) years. At TAF initiation, the median CD4 count was 557 cells\/\u00b5L, the median eGFR was 80\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, and 86% had suppressed HIV infection. The mean adjusted eGFR slope during TDF and TAF exposure was \u22122.08 [95% confidence interval (CI) \u22122.24, \u22121.92] and 1.18 (95% CI 0.20, 1.52) mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>\/year, respectively (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Individuals who experienced rapid eGFR decline (&gt;\u00a03 or 5\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>\/year) while receiving TDF experienced significant eGFR recovery while on TAF (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Significant improvement in eGFR slope was observed in patients who switched from TDF\u2010 to TAF\u2010containing antiretroviral regimens. These data provide further support for the renal safety of TAF, and for switching those who experience progressive worsening of renal function from TDF to TAF.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12899","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T23:54:45Z","timestamp":1595462085000},"page":"607-612","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Estimated glomerular filtration rate slopes on tenofovir alafenamide"],"prefix":"10.1111","volume":"21","author":[{"given":"F","family":"Ibrahim","sequence":"first","affiliation":[{"name":"King\u2019s College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Campbell","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AC","family":"Bailey","sequence":"additional","affiliation":[{"name":"Imperial NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Stockwell","sequence":"additional","affiliation":[{"name":"Brighton and Sussex NHS Trust Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-1775","authenticated-orcid":false,"given":"L","family":"Waters","sequence":"additional","affiliation":[{"name":"Mortimer Market Centre London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Orkin","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Johnson","sequence":"additional","affiliation":[{"name":"Royal Free Hospital NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-325X","authenticated-orcid":false,"given":"M","family":"Gompels","sequence":"additional","affiliation":[{"name":"North Bristol NHS Trust Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"De Burgh\u2010Thomas","sequence":"additional","affiliation":[{"name":"Gloucester NHS Trust Gloucester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Jones","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Schembri","sequence":"additional","affiliation":[{"name":"Central Manchester University Hospitals NHS Foundation Trust Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PW","family":"Mallon","sequence":"additional","affiliation":[{"name":"University College Dublin Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2844-1612","authenticated-orcid":false,"given":"FA","family":"Post","sequence":"additional","affiliation":[{"name":"King\u2019s College London London UK"},{"name":"King\u2019s College Hospital NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328351f68f"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00211-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350701200812"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283262a64"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000736"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.01.010"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu107"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.07.009"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000958"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31827ce4ee"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12401"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002223"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001186"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr657"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001353"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3040"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0180"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.020"},{"key":"e_1_2_7_20_1","first-page":"91","article-title":"Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV\u2010infected patient","volume":"5","author":"Mothobi NZ","year":"2018","journal-title":"Ther Adv Infect Dis"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12819"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12249"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.12899","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T16:15:15Z","timestamp":1693152915000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1111\/hiv.12899"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12899","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"2020-05-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}